Contact Information

Currently Enrolling Trials

General Information

Ketoprofen, the generic equivalent of Wyeth Ayerst's Oruvail, has received approval as a non-steroidal anti-inflammatory. Ketoprofen will be available in 200 mg extended release capsules.

Approval Date: 1997-12-01

Company Name: Schein Pharmaceutical

Back to Listings

26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
11Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
26Apr
MAGI's Clinical Research vConference — Spring 2021

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here

Ketoprofen

Profile

Contact Information

Currently Enrolling Trials

General Information

Upcoming Events

Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

Medical Device Clinical Trials in China: Latest Regulatory Developments

Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

MAGI's Clinical Research vConference — Spring 2021

Featured Products

Regenerative Medicine: Steps to Accelerate Development

Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

Simple Changes Can Make Trials More Patient Friendly

Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.